Fig. 7
From: Application of lipid nanovesicle drug delivery system in cancer immunotherapy
Reprint with permission from [88]. Copyright 2021, Ivyspring International Publisher
a Schematic of preparation of CD64-NVs-aPD-L1-CP and immune boosting mechanism of NVs. b Average tumor sizes for the treated mice (n = 5). The experimental data were shown as mean ± SEM. c Survival curves for the mice treated with PBS (#1), CD64-NVs (#2), CD64-NVs-aPD-L1 (#3), CD64-NVs-CP (#4), CP + aPD-L1 (#5) and CD64-NVs-CP-aPD-L1 (#6) groups. (n = 5). d Representative plots of T cells in tumors of different treatment detected by flow cytometry (Gated on CD3+). e Representative plots of Foxp3 in Tregs infiltrating in tumors detected by the flow cytometry (gated on CD4+).